Key Drivers
- Improving Cash Flow
- Strong Net Cash
- Ongoing Losses
AIAI Summary
Tarsus has evolved from an XDEMVY launch story into a platform bet, with strong sales, 93% gross margins, and net cash positioning it for an earnings inflection—if expense growth finally trails revenue growth. Investors should favor the shares only while XDEMVY momentum sustains and cash-flow conversion proves repeatable, as the long-dated Alkeus pipeline adds upside but also dilution and execution risk.
Price Chart
Financial Metrics
Deep Analysis
Research tool. Not personalized advice.
Fundamental Analysis
Key Financial Insights:
- •Improving Cash Flow
- •Strong Net Cash
- •Ongoing Losses
TARS has strong liquidity and improving cash flow, but persistent losses, high costs, dilution, and demanding valuation warrant caution.
Price Behavior
Key Price Behavior Insights:
- •Positive Monthly Trend
- •Post-Peak Pullback
- •Neutral Momentum
TARS remains positive over the last month but is consolidating after a sharp pullback; hold above $77.60–$78.20 and reclaim $82.80–$83.20 for a stronger rebound outlook.
Sharp retreat of roughly 14% from the $90.78 peak to $78.09
Sentiment & News
Key News Insights:
- •Alkeus acquisition
- •Phase 3 asset
- •Institutional buying
Tarsus's Alkeus acquisition adds promising Phase 3 Stargardt candidate gildeuretinol, broadening retinal-disease exposure amid supportive clinical, regulatory, and institutional-investor developments.
The developments are strategically positive for Tarsus, potentially strengthening its long-term ophthalmology growth profile
Similar Companies in Healthcare
Other companies in the same sector with AI ratings